BR112021019999A2 - Formulação de comprimido vaginal - Google Patents

Formulação de comprimido vaginal

Info

Publication number
BR112021019999A2
BR112021019999A2 BR112021019999A BR112021019999A BR112021019999A2 BR 112021019999 A2 BR112021019999 A2 BR 112021019999A2 BR 112021019999 A BR112021019999 A BR 112021019999A BR 112021019999 A BR112021019999 A BR 112021019999A BR 112021019999 A2 BR112021019999 A2 BR 112021019999A2
Authority
BR
Brazil
Prior art keywords
tablet formulation
vaginal tablet
vaginal
glucone
lactone
Prior art date
Application number
BR112021019999A
Other languages
English (en)
Inventor
Annette Säfholm
Helena Strevens
Nils-Olof Lindberg
Olov Sterner
Sophie Manner
Ulf Ellervik
Original Assignee
Gedea Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gedea Biotech Ab filed Critical Gedea Biotech Ab
Publication of BR112021019999A2 publication Critical patent/BR112021019999A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)

Abstract

formulação de comprimido vaginal. a presente invenção se refere a uma composição farmacêutica que compreende glucona-d-lactona, que é adequado para uso no tratamento de infecções microbianas vaginais.
BR112021019999A 2019-04-05 2020-04-03 Formulação de comprimido vaginal BR112021019999A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19167495 2019-04-05
PCT/EP2020/059582 WO2020201515A1 (en) 2019-04-05 2020-04-03 Vaginal tablet formulation

Publications (1)

Publication Number Publication Date
BR112021019999A2 true BR112021019999A2 (pt) 2021-12-07

Family

ID=66101895

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019999A BR112021019999A2 (pt) 2019-04-05 2020-04-03 Formulação de comprimido vaginal

Country Status (24)

Country Link
US (1) US20220193031A1 (pt)
EP (1) EP3976000B1 (pt)
JP (1) JP2022537478A (pt)
KR (1) KR20210148195A (pt)
CN (1) CN113660928B (pt)
AR (1) AR118580A1 (pt)
AU (1) AU2020252268A1 (pt)
BR (1) BR112021019999A2 (pt)
CA (1) CA3134086A1 (pt)
CL (1) CL2021002430A1 (pt)
CO (1) CO2021014253A2 (pt)
EA (1) EA202192716A1 (pt)
ES (1) ES2961736T3 (pt)
HU (1) HUE062772T2 (pt)
IL (1) IL286942A (pt)
MA (1) MA56011A (pt)
MX (1) MX2021012146A (pt)
PE (1) PE20220381A1 (pt)
PL (1) PL3976000T3 (pt)
SG (1) SG11202110236QA (pt)
TW (1) TW202103693A (pt)
UA (1) UA127823C2 (pt)
WO (1) WO2020201515A1 (pt)
ZA (1) ZA202106877B (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165139T3 (es) * 1998-04-30 2002-03-01 Vesely Renata Maria Cavaliere Composiciones farmaceuticas que contienen lactobacillus brevis y lactobacillus salivarius para el tratamiento de infecciones vaginales.
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20030017207A1 (en) * 2001-05-01 2003-01-23 Lin Shun Y. Compositions and methods for treating vulvovaginitis and vaginosis
ITBO20110461A1 (it) * 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
MY198473A (en) 2016-04-06 2023-08-31 Gedea Biotech Ab Glucono delta-lactone for treatment of vaginal fungal infections
EP3691625A1 (en) 2017-10-06 2020-08-12 Gedea Biotech AB Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections

Also Published As

Publication number Publication date
AR118580A1 (es) 2021-10-20
ES2961736T3 (es) 2024-03-13
PL3976000T3 (pl) 2023-12-04
KR20210148195A (ko) 2021-12-07
EP3976000C0 (en) 2023-08-02
EP3976000B1 (en) 2023-08-02
CA3134086A1 (en) 2020-10-08
JP2022537478A (ja) 2022-08-26
CL2021002430A1 (es) 2022-07-01
EA202192716A1 (ru) 2022-01-17
TW202103693A (zh) 2021-02-01
UA127823C2 (uk) 2024-01-10
PE20220381A1 (es) 2022-03-18
WO2020201515A1 (en) 2020-10-08
CO2021014253A2 (es) 2021-11-19
US20220193031A1 (en) 2022-06-23
IL286942A (en) 2021-12-01
CN113660928B (zh) 2024-04-05
MA56011A (fr) 2022-04-06
MX2021012146A (es) 2021-12-10
EP3976000A1 (en) 2022-04-06
ZA202106877B (en) 2023-03-29
SG11202110236QA (en) 2021-10-28
CN113660928A (zh) 2021-11-16
HUE062772T2 (hu) 2023-12-28
AU2020252268A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
DOP2017000137A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo.
GT201500088A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
BR112016019592A8 (pt) Composto, uso de um composto, e, composição farmacêutica
CL2012002551A1 (es) Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor.
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
UY37538A (es) Amidas aromáticas de ácidos carboxílicos
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
CL2019002020A1 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer.
BR112021019999A2 (pt) Formulação de comprimido vaginal
BR112016029619A2 (pt) novas fluoroquinolonas e sesu usos no tratamento de infecções bacterianas